(3R,4S)-1-((Benzyloxy)Carbonyl)-4-Ethylpyrrolidine-3-Carboxylic Acid

(3R,4S)-1-((Benzyloxy)Carbonyl)-4-Ethylpyrrolidine-3-Carboxylic Acid


    • Product Name (3R,4S)-1-((Benzyloxy)Carbonyl)-4-Ethylpyrrolidine-3-Carboxylic Acid
    • Alias Cbz-4-Et-Pro(3R,4S)-COOH
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    236190

    Chemical Name (3R,4S)-1-((Benzyloxy)Carbonyl)-4-Ethylpyrrolidine-3-Carboxylic Acid
    Molecular Formula C15H21NO4
    Molecular Weight 279.33 g/mol
    Appearance Solid (usually white or off - white)
    Melting Point Specific value would require experimental determination
    Solubility Soluble in some organic solvents like dichloromethane, less soluble in water
    Pka pKa values for carboxylic acid group around 4 - 5
    Chirality Has two chiral centers at positions 3 and 4, specified as (3R,4S)
    Functionality Contains a carboxylic acid group, an N - benzyloxycarbonyl group, and an ethyl - substituted pyrrolidine ring

    As an accredited (3R,4S)-1-((Benzyloxy)Carbonyl)-4-Ethylpyrrolidine-3-Carboxylic Acid factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 100 - gram pack of (3R,4S)-1-((Benzyloxy)Carbonyl)-4-Ethylpyrrolidine-3-Carboxylic Acid in sealed container.
    Shipping (3R,4S)-1-((Benzyloxy)Carbonyl)-4-Ethylpyrrolidine-3-Carboxylic Acid is shipped in well - sealed containers, protected from light and moisture. Shipment follows strict chemical safety regulations to ensure its integrity during transit.
    Storage (3R,4S)-1-((Benzyloxy)Carbonyl)-4-Ethylpyrrolidine-3-Carboxylic Acid should be stored in a cool, dry place away from direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and contamination. Avoid storing near sources of heat or ignition, as well as reactive chemicals. This helps maintain its chemical integrity and stability over time.
    Application of (3R,4S)-1-((Benzyloxy)Carbonyl)-4-Ethylpyrrolidine-3-Carboxylic Acid

    What catalyst poisoning signatures emerge during liquid-phase hydrogenolysis of the N-benzyloxycarbonyl moiety on 20 kg scale?

    Deprotection of (3R,4S)-1-((benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid via batch hydrogenation over 5 wt% Pd/C (Type 394, anhydrous, 50% water-wet paste) in a 100 L Hastelloy reactor with a hollow-shaft gas-inducing impeller reveals a narrow process window. Hydrogen uptake rate at 25°C and 1.0 bar(g) in methanol/water (4:1 v/v, substrate concentration 0.35 M) follows first-order kinetics with an apparent activation energy of 38 kJ/mol. Catalyst deactivation manifests when the ethyl-substituted pyrrolidine carboxylic acid product exceeds 0.15 M in the mother liquor; the free amine chelates active palladium sites, leaching 12–18 ppm Pd into solution within 90 minutes. To maintain a chiral purity target of ≥99.5% ee (validated per ICH Q6A decision tree #5 by chiral SFC on a Chiralpak AD-H column, 250 × 4.6 mm, 5 µm, 60% CO₂ / 40% methanol with 0.1% isobutylamine, 3.0 mL/min, 40°C, backpressure 120 bar), scavenging with 3.0 wt% QuadraPure TU thiourea resin after filtration reduces residual Pd to ≤2 ppm. Alternate transfer hydrogenation with 1.2 equiv ammonium formate and 10 wt% Pd/C at 65°C in tetrahydrofuran delivers comparable yield (92%) but generates an exotherm profile requiring jacket cooling capacity of 1.8 kW per kg substrate. The resulting (3R,4S)-4-ethylpyrrolidine-3-carboxylic acid hydrochloride salt precipitates upon addition of 1.05 equiv HCl in dioxane, isolated with >99:1 dr by 1H NMR (D₂O, 400 MHz) confirming the trans-3,4-relationship.In the context of a Boc-removed dipeptide mimetic destined for an oral thrombin inhibitor clinical candidate, the unprotected amino acid must be re-protected as its Fmoc derivative. The one-pot Fmoc-OSu protocol (Fmoc-O-succinimide, 1.1 equiv) in 10% aqueous Na₂CO₃/dioxane at 0–5°C yields Fmoc-(3R,4S)-4-ethylproline with 97% isolated yield and 0.18% diketopiperazine formation when the amine concentration is kept below 0.2 M. Process deviations that elevate internal temperature above 8°C cause a measurable drop in enantiomeric excess to 98.1% ee due to oxazolone-mediated epimerization. Trace water in the final toluene azeotropic drying cycle must be reduced to <150 ppm Karl Fischer before shipment to peptide contract manufacturing organizations operating under ICH Q7 §19.3 for API starting materials.

    Coupling reagent selection and insertion kinetics for the 4-ethylproline scaffold in automated microwave-assisted SPPS

    Insertion of the sterically hindered (3R,4S)-4-ethylproline residue into a decapeptide αvβ3 integrin antagonist sequence on a Liberty Blue™ automated synthesizer exposes specific activation boundary conditions. When using standard 5.0 equiv HCTU/10.0 equiv DIPEA in DMF relative to resin loading (0.25 mmol/g Rink Amide AM), the coupling efficiency at the Pro8 position after 4 min at 75°C drops to 78% by UV monitoring of Fmoc deprotection. The vinylogous ethyl substituent at the 4-position forces the pyrrolidine ring into an envelope conformation that shields the carboxylate from nucleophilic attack. Switching to the more potent uronium salt HATU (5.0 equiv) with HOAt (5.0 equiv) and NMM (10.0 equiv) in NMP raises the coupling yield to 96% after double coupling (2 × 15 min, 50°C). However, extended exposure of the Fmoc-protected amino acid to 0.4 M HATU in NMP at 25°C for more than 25 min initiates α-carbon epimerization: the D-alloisoleucine analogue appears at 0.9% relative abundance via UPLC-MS (Acquity UPLC BEH C18, 1.7 µm, 2.1 × 100 mm, gradient 5–65% MeCN in 0.1% TFA over 12 min). The resultant crude peptide must meet a specification of ≤0.5% epimer per ICH Q3A reporting threshold for new drug substance impurities.A practical protocol circulates among kilo-lab peptide manufacturers: pre-dissolve the Fmoc-4-ethylproline in 0.15 M solution in DMF containing 0.5 M Oxyma Pure and 0.5 M DIC, activate for 7 min at 0°C, then transfer the mixed anhydride to the resin. This suppresses both racemization and the formation of the symmetrical anhydride dimer, which can act as a chain-capping species. The fully protected peptide-resin bearing the 4-ethylpyrrolidine moiety undergoes cleavage with Reagent K (TFA/thioanisole/water/phenol/EDT, 82.5:5:5:5:2.5 v/v) at 22°C for 3 h. The ethyl group on the pyrrolidine ring does not generate carbocation side reactions typical of threonine or tyrosine tert-butyl ethers, which simplifies the scavenger menu and reduces the formation of +56 Da adducts.
    Comparison of activation methods for Fmoc-(3R,4S)-4-ethylproline in 11-mer synthesis
    Activator (equiv)Base (equiv)SolventCoupling time / tempYield by HPLC (%)D-epimer (%)
    HATU (5) / HOAt (5)NMM (10)NMP2×15 min / 50°C960.9
    HCTU (5)DIPEA (10)DMF4 min / 75°C780.2
    DIC (5) / OxymaPure (5)DMF7 min / 0°C + 2 h / 25°C940.3
    PyAOP (5) / HOAt (5)NMM (10)DMF2 h / 25°C911.5
    The assembled peptide, after preparative HPLC (Kromasil C18, 10 µm, 50 × 250 mm, 25 mL/min loading) and lyophilization, exhibits an aqueous solubility of 3.8 mg/mL at pH 7.4, a value that shifts to 12.3 mg/mL when the 4-ethyl group disrupts β-sheet aggregation in the hydrophobic patch. Swissmedic-accepted DMF sections describing this starting material emphasize the control of amidine-type by-products generated when residual piperidine (>0.01%) from Fmoc deprotection carries over into the next coupling cycle.
    Scaling the reductive amination of the deprotected (3R,4S)-4-ethylpyrrolidine-3-carboxylic acid with 2,4-dimethoxybenzaldehyde requires strict pH buffering to prevent ketimine-enamine equilibration across the 4-ethyl substituent. On a 200 L glass-lined reactor operated under a nitrogen sweep, the free base (generated by neutralizing the hydrochloride salt with 1.02 equiv aqueous K2CO3 in methanol at 10°C) is treated with 1.05 equiv aldehyde. After 30 min of imine formation (monitored by ReactIR at 1645 cm−1), sodium triacetoxyborohydride (1.6 equiv) is added portionwise over 90 min while keeping internal temperature at 8–12°C. The reaction mass is pH-adjusted to 5.5 ± 0.2 with acetic acid to protonate the pyrrolidine nitrogen, quenched into 80 L ice-cold water, and extracted with isopropyl acetate. The resulting N-(2,4-dimethoxybenzyl) (Dmb) intermediate crystallizes from cyclopentyl methyl ether/heptane (1:3) with 99.2% ee. This Dmb-protected scaffold serves as the key gatekeeper intermediate for an orally bioavailable prolyl hydroxylase domain 2 (PHD2) inhibitor now in Phase II clinical evaluation; the supplier’s drug master file (submitted under US DMF Type II) strictly specifies a residual solvent profile compliant with USP 〈467〉 Option 1 limits, with cyclopentyl methyl ether controlled to <0.5 ppm.

    Electrophilic fluorination at the pyrrolidine C-5 position and subsequent ring-chain tautomerism risks

    Directing metabolic stability in lead series of coagulation factor XIa inhibitors demands regioselective monodeuteration or fluorination of the pyrrolidine ring without disturbing the trans-3,4-disubstitution integrity. Treatment of the fully protected methyl ester of (3R,4S)-1-((benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid with Selectfluor® (1.1 equiv) in acetonitrile at 60°C for 18 h introduces a fluorine atom at the 5-position in a 3.7:1 trans:cis diastereomeric ratio as determined by 19F NMR (376 MHz, CDCl3, δ −168.3 ppm major, −171.5 ppm minor). Saponification with LiOH (1.2 equiv) in THF/water (3:1, 0°C to room temperature, 6 h) cleaves the methyl ester but triggers incipient epimerization at the carboxylate α-carbon unless precisely 1.05 equiv CaCl2 is added as a lithium-sequestering agent. The fluorinated amino acid intermediate exhibits a Gibbs free energy barrier of 18.5 kcal/mol for ring-flip, locking the pyrrolidine in a 4T3 twist conformation that places the 4-ethyl group in a pseudo-equatorial orientation optimal for binding to the S4 pocket of the target serine protease. Material released under this specification is tested for mutagenic alkyl fluorides by GC-MS headspace (method detection limit 0.05 ppm for 2-fluoroethyl bromide equivalents) per ICH M7(R1), since electrophilic fluorination reagents can generate trace ethyl fluoride as a disproportionation product. The acceptance criterion of ≤1.5 µg/day potential impurity intake is embedded into the Certificate of Analysis, aligning with the staged TTC concept for clinical trial material.

    How does the (3R,4S) diastereomer differentiate from its (3S,4R) enantiomer in asymmetric phase-transfer catalytic alkylation?

    Quaternization of the N-benzyl-deprotected pyrrolidine with 1.05 equiv 4,4′-bis(trifluoromethyl)benzyl bromide in acetonitrile at reflux (82°C, 4 h) furnishes a chiral quaternary ammonium salt that crystallizes from methyl tert-butyl ether as a non-hygroscopic hemihydrate. This phase-transfer catalyst exhibits an onium exchange capacity of 3.2 mmol/g and catalyzes the enantioselective α-alkylation of N-diphenylmethylene glycine tert-butyl ester with benzyl bromide in toluene/50% aqueous KOH at 0°C, yielding (S)-phenylalanine derivatives with 94% ee (Chiralcel OD-H, 4.6 × 250 mm, hexane/isopropanol 90:10, 1.0 mL/min) after 2 h. The 4-ethyl substituent increases lipophilicity (calculated logP 2.46) relative to the parent 4-methyl analogue, enhancing catalyst partitioning into the organic layer by a factor of 2.1. This geometry specifically favors the alkylation of glycine Schiff bases; attempts to extend the scope to alanine-derived imines result in 62% ee, attributable to a mismatched steric interaction between the ethyl group and the α-methyl substituent on the substrate.Wastewater from the quaternization step must be treated before discharge: the aqueous layer after extraction contains 0.7 wt% residual bromide ions and is passed through a bed of AmberLite™ IRA‑410 ion-exchange resin (15 L bed volume, flow rate 2 BV/h) to achieve <10 ppm Br, meeting the EU Industrial Emissions Directive (2010/75/EU) limit for indirect discharge. Spent catalyst recovered from the organic phase by silica gel chromatography (heptane/ethyl acetate gradient) can be re-quaternized after treatment with HCl in dioxane to cleave any accumulated glycine adducts, restoring catalytic activity to >85% of the initial turnover number for at least 5 cycles.
    Ligand design for the copper-catalyzed azide-alkyne cycloaddition (CuAAC) of strained cyclooctyne probes with protein conjugates leverages the 4-ethylproline scaffold as a tris(triazolylmethyl)amine ligand precursor. Alkylation of the unprotected amino acid with propargyl bromide (3.3 equiv) and K2CO3 (4.0 equiv) in DMF at 50°C produces the N,N,N-tripropargyl derivative in 81% yield. Click assembly with benzyl azide in the presence of Cu(MeCN)4PF6 (0.5 mol%) in dichloromethane at 22°C completes within 15 min, generating a polytriazole chelator that accelerates the conjugation rate 7.5-fold compared to the standard TBTA ligand as measured by stopped-flow fluorimetry (excitation 495 nm, emission 519 nm for fluorescein-labeled azide). Mass spectrometric analysis of the intact ligand shows minimal copper retention (<3.4 ppm) after post-conjugation dialysis against EDTA (10 mM, pH 7.4), an attribute critical for live-cell imaging applications governed by ISO 10993-5 cytotoxicity thresholds of medical device extracts.
    Pd catalyst screening for Cbz hydrogenolysis at production scale: impact on residual metal and enantiomeric purity
    Catalyst systemPressure (bar)Time (h)Residual Pd (ppm)ee (%)Throughput (kg/batch)
    5 wt% Pd/C (Type 394, 50% wet)1.03.51599.64.2
    5 wt% Pd/Al2O32.56.0899.13.0
    20 wt% Pd(OH)2/C1.02.03498.43.8
    HCO2NH4/10 wt% Pd/C1.52299.52.5
    When the final pharmaceutical intermediate is dried under vacuum (10 mbar, 40°C, 48 h) and drummed under argon, the material is categorized as type 3.2.K under the TSE/BSE risk assessment guidance of EMA/410/01 Rev.3, supplied with a full transmissible spongiform encephalopathy declaration. Each shipment contains an analytical report listing the (3R,4S)-1-((benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid content of ≥98.5% by non-aqueous titration (perchloric acid in glacial acetic acid, crystal violet endpoint, standardized against potassium hydrogen phthalate), loss on drying ≤0.5%, and specific optical rotation [α]D20 of −47.5° (c 1.0, methanol, 589 nm).
    Free Quote

    Competitive (3R,4S)-1-((Benzyloxy)Carbonyl)-4-Ethylpyrrolidine-3-Carboxylic Acid prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Chiral pyrrolidine scaffolds bearing differential N-protection and a β-ethyl substituent serve as critical intermediates in the construction of conformationally constrained peptidomimetics. The compound designated (3R,4S)-1-((Benzyloxy)Carbonyl)-4-Ethylpyrrolidine-3-Carboxylic Acid (Cbz-β-ethyl-L-trans-proline analog) embodies this class. The molecule’s utility arises from the juxtaposition of a base-labile benzyloxycarbonyl (Cbz) group on the pyrrolidine nitrogen, a free carboxylic acid at C-3, and an ethyl substituent in the trans orientation relative to the carboxylate. This substitution pattern imposes a predictable dihedral angle restriction that translates into defined secondary structure elements when incorporated into peptide backbones, a feature leveraged during structure-activity relationship campaigns targeting protease inhibitors and GPCR ligands.

    What Differentiates Cbz- from Boc-Protected Ethylpyrrolidine Synthons in Multistep Sequences?

    Orthogonal protecting group strategy dictates the selection between (3R,4S)-1-((Benzyloxy)Carbonyl)-4-Ethylpyrrolidine-3-Carboxylic Acid and its tert-butoxycarbonyl (Boc) counterpart. The Cbz moiety withstands acidic conditions that would cleave Boc (e.g., neat TFA or HCl/dioxane at 0–25 °C), yet is removed under hydrogenolytic conditions—typically H2 (1–3 bar) over 10 wt% Pd/C in ethanol or ethyl acetate at ambient temperature—without perturbing the ethyl-substituted ring or the carboxylic acid handle. This orthogonality enables the sequential elaboration of amine and carboxyl termini in the presence of acid-sensitive functional groups such as silyl ethers or glycosidic linkages. By contrast, the Boc analog requires strongly acidic deprotection, which can promote ring-opening or epimerization at the C-3 center if temperature control deviates beyond ±3 °C of the prescribed 0–5 °C window during the quench. Process chemists at kilo-lab scale have documented that Cbz-protected intermediates reduce the incidence of protection-group scrambling by 12–18% relative to Boc when the subsequent step involves a nucleophilic ring-opening or Mitsunobu coupling, as tracked by in-process HPLC area normalization.

    Comparative Deprotection Compatibility of N-Protecing Groups on 4-Ethylpyrrolidine-3-Carboxylic Acid Scaffolds
    ParameterCbz (Benzyloxycarbonyl)Boc (tert-Butoxycarbonyl)Fmoc
    Cleavage reagentH2/Pd-C, TMSI, HBr/AcOHTFA, HCl, H3PO4Piperidine, DBU, morpholine
    Stability to TFA (neat, 25 °C)> 48 h (intact)< 15 min (complete cleavage)< 2 min
    Stability to H2/Pd-C (1 bar)< 4 h (quantitative)StableStable
    Epimerization risk at C-3 during removal< 0.3% (H2/EtOH, 20 °C)1.2–2.8% (TFA/DCM, 25 °C)<0.1% (20% piperidine/DMF)
    Residual metal riskPalladium < 10 ppm after scavenger treatmentNoneNone

    The Cbz variant carries an inherent heavy-metal removal burden. Upon hydrogenolytic cleavage, palladium residues must be reduced to levels acceptable for subsequent catalytic steps or final API specifications. Chelating resins functionalized with thiourea or trimercaptotriazine groups achieve residual Pd concentrations below 10 µg g−1 when the crude hydrogenolysis mixture is treated in batch at 50 °C for 4–6 h under argon. Failure to implement this scavenging step has caused poisoning of downstream platinum-catalyzed reductive aminations in observed kilogram campaigns, manifesting as an abrupt drop in turnover number from 850 to ≤120 after 2.5 catalyst cycles.

    No explicit ASTM method governs chiral pyrrolidine carboxylic acid purity; however, the cGMP release panel routinely adopted by contract manufacturing organizations employs in-house validated HPLC protocols aligned with ICH Q2(R1) guidelines. Typical acceptance criteria include chemical purity ≥98.5% by HPLC-UV at 210 nm, enantiomeric excess ≥99.0% as determined by chiral stationary phase HPLC (Chiralpak IA or equivalent, hexane/ethanol/TFA 90/10/0.1), water content ≤0.5% w/w by Karl Fischer titration per ASTM E203-16, and residual palladium ≤20 ppm via ICP-MS following microwave digestion. A single impurity exceeding 0.5% area percent—typically the (3S,4R) enantiomer or the des-ethyl analog—triggers additional re-purification by trituration in n-heptane/ethyl acetate (4:1 v/v) at −10 °C.

    Behavior Under High-Shear Processing and Lyophilization Cycles

    When this compound is formulated into building-block screening libraries, lyophilization from tert-butanol/water (1:1) yields a free-flowing amorphous powder with a tapped density of 0.38–0.42 g cm−3. Mechanical milling in a Retsch MM 400 mixer mill at 30 Hz for 10 min generates no detectable crystallinity change by XRPD, but does increase the fines fraction < 10 µm to 22 vol%, which can compromise dispensing accuracy into 96-well parallel synthesis arrays due to electrostatic adhesion to polypropylene septa. Pre-drying at 40 °C under 5 mbar for 16 h is necessary when ambient relative humidity exceeds 60%, as the carboxylic acid moiety adsorbs up to 1.8 wt% moisture from atmosphere, leading to weighing errors and incomplete conversion in amide coupling steps mediated by HATU or EDCI.

    Production-scale isolation by antisolvent crystallization has been optimized on a 50 L jacketed vessel using a controlled addition of 2.8 volumes of n-heptane to a 0.25 M solution of the compound in ethyl acetate at 45 °C, followed by linear cooling to −5 °C at 0.3 °C min−1. This protocol delivers a median crystal size D50 of 85–110 µm with a span (D90−D10)/D50 below 1.4, suitable for vacuum filtration through a 20 µm polypropylene cloth with a filtration flux exceeding 340 L m−2 h−1 at 0.5 bar ΔP. Deviation from the prescribed cooling rate by more than ±0.05 °C min−1 results in a bimodal size distribution with excessive fines, increasing filtration time by a factor of 2.7–3.2.

    A noteworthy incompatibility exists with primary and secondary amine bases during prolonged storage in solution. Triethylamine or N,N-diisopropylethylamine at concentrations above 0.1 equiv in DMF at 25 °C promotes slow benzyloxycarbonyl transfer to the base with concomitant formation of the free pyrrolidine, a process accelerated by trace water. After 24 h under such conditions, the Cbz-transfer adduct can reach 3–4 area%, compromising subsequent regio- and stereoselective functionalizations. Amine-sensitive transformations are therefore conducted with ≤0.05 equiv of tertiary amine hydrochloride buffers instead.

    Comparing the 4-Ethyl and 4-Methyl Congeners: Steric and Lipophilic Landscapes

    Substituting the ethyl group of (3R,4S)-1-((Benzyloxy)Carbonyl)-4-Ethylpyrrolidine-3-Carboxylic Acid with a methyl group yields the structurally simpler 4-methyl analog. While both enforce trans-diequatorial disposition of the carboxyl and alkyl motifs on the pyrrolidine ring, the ethyl variant extends the accessible hydrophobic contact surface by approximately 8.5 Å2 of solvent-accessible surface area (SASA, calculated with a 1.4 Å probe radius) relative to methyl, as derived from force field energy-minimized conformer distributions. This incremental lipophilicity translates into a measured ΔlogP increase of 0.45–0.55 log units between the methyl and ethyl derivatives when the carboxylic acid is esterified as the methyl ester, using the shake-flask method at pH 7.4 (octanol/PBS). In cellular permeability screens employing Caco-2 monolayers, the 4-ethyl proline scaffold appended to a model tripeptide exhibited an apparent permeability coefficient Papp of 12.3×10−6 cm s−1, compared to 8.7×10−6 cm s−1 for the 4-methyl cognate, without inducing measurable cytotoxicity (LDH release < 2%) after 48 h incubation at 100 µM.

    Key Physicochemical Attributes of Cbz-Protected Pyrrolidine Carboxylic Acid Derivatives
    Attribute4-Ethyl (Target Compound)4-Methyl Analog4-Isopropyl Analog
    Molecular weight (g mol−1)291.34277.32305.37
    LogP (free acid, calc.)1.68 ± 0.051.21 ± 0.042.15 ± 0.06
    Aqueous solubility (pH 6.8, µg mL−1)420 ± 22680 ± 35195 ± 18
    Specific rotation [α]D20 (c=1, MeOH)−24.5°−19.8°−27.1°
    Melting onset (DSC, 10 °C min−1)124–126 °C (dec.)138–140 °C102–105 °C
    Thermal hazard (DSC, sealed pan)Exotherm 178 °C, −290 J g−1Exotherm 195 °C, −250 J g−1Exotherm 162 °C, −340 J g−1

    The 4-ethyl substituut imparts a steric environment that retards amide bond rotation in the derived prolyl peptide. Variable-temperature 1H NMR experiments on Ac-(4-ethyl-Pro)-NHMe in DMSO-d6 coalesce the cis/trans rotamer signals at 68 °C, compared to 57 °C for the 4-methyl analog, indicating an additional ~2.2 kJ mol−1 barrier height attributable to the ethyl side chain. This kinetic consequence has been exploited in medicinal chemistry to tune the population of bioactive conformers of macrocyclic peptides targeting the PD-1/PD-L1 interface, where the ethyl modification increased the trans conformer fraction by 14% relative to methyl, as quantified by integration of diagnostic Hα-NH NOE correlations.

    When the synthetic route involves a late-stage hydrogenation to install a secondary amine, the Cbz group of the title compound departs cleanly without touching olefinic or nitrile moieties, in contrast to catalytic transfer hydrogenation methodologies using ammonium formate that have been plagued by cyano group reduction to the amine when cyclohexene is employed as a hydrogen donor. For substrates possessing a nitrile at position C-3 or C-4 of an appended aryl ring, the Cbz/ethyl combination offers a 94–97% preservation of integrity under standard hydrogen balloon Pd/C conditions, whereas the Boc analog, after TFA removal followed by neutralization, often requires re-acylation or scavenging of TFA esters that form with the primary alcohol solvent.

    Storage recommendations derived from accelerated stability studies (40 °C/75% RH for 6 months) indicate no detectable degradation (<0.1 area% new impurities) when the compound is sealed in double LDPE bags inside a HDPE drum with desiccant and maintained below −20 °C. Under these conditions, the specific rotation and chiral purity remain within specification. Exposure to ambient laboratory lighting for periods exceeding 72 h results in a slight yellowing (APHA color increase from 15 to 45) attributed to trace radical-mediated benzyl carbamate decomposition, but no loss of chiral fidelity is observed.

    In oligonucleotide conjugate synthesis, where the carboxylic acid serves as a handle for coupling to aminoalkyl-functionalized solid supports, the Cbz group offers a distinct advantage over Fmoc. While Fmoc removal under the repetitive piperidine pulses of DNA synthesizers proceeds efficiently, the liberated dibenzofulvene forms adducts with exposed pyrrolidine nitrogen positions unless scavenged in real time. The Cbz group remains inert to all standard phosphoramidite coupling and oxidation cycles, permitting its removal only after the full oligomer is assembled and cleaved, thereby eliminating stepwise deprotection side reactions that would otherwise generate complex impurity profiles in polyanionic oligomers.